Table 1.
Patient characteristics
| Variable | All patients | BMI <23 kg/m2 | BMI ≥23 to <25 kg/m2 | BMI ≥25 to <28 kg/m2 | BMI ≥28 kg/m2 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | Ipragliflozin | Placebo | Ipragliflozin | Placebo | Ipragliflozin | Placebo | Ipragliflozin | Placebo | Ipragliflozin | |
| n | 321 | 508 | 93 | 113 | 74 | 113 | 80 | 144 | 74 | 138 |
| Male (%) | 214 (66.7) | 337 (66.3) | 67 (72.0) | 76 (67.3) | 48 (64.9) | 76 (67.3) | 51 (63.8) | 104 (72.2) | 48 (64.9) | 81 (58.7) |
| Age (years) | 57.5 ± 10.0 | 57.8 ± 10.5 | 60.7 ± 8.5 | 61.0 ± 9.9 | 57.9 ± 9.8 | 59.9 ± 9.2 | 58.0 ± 9.6 | 57.7 ± 9.5 | 52.4 ± 10.7 | 53.7 ± 11.5 |
| BMI (kg/m2) | 25.4 ± 3.6 | 26.0 ± 3.8* | 21.6 ± 1.0 | 21.6 ± 0.9 | 23.9 ± 0.6 | 24.1 ± 0.5 | 26.5 ± 0.9 | 26.3 ± 0.9 | 30.5 ± 2.5 | 31.0 ± 2.8 |
| WC (cm) | 89.0 ± 9.5 | 90.0 ± 9.8 | 80.3 ± 5.0 | 79.2 ± 4.7 | 85.7 ± 4.8 | 86.7 ± 4.5 | 91.2 ± 5.3 | 90.7 ± 5.9 | 100 ± 7.7 | 101 ± 8.2 |
| Duration of DM ≥60 months (%) | 204 (63.8) | 310 (61.4) | 70 (76.1) | 83 (74.1) | 49 (66.2) | 76 (67.3) | 46 (57.5) | 86 (60.1) | 39 (52.7) | 65 (47.4) |
| No history of smoking (%) | 102 (40.5) | 181 (41.5) | 27 (37.0) | 46 (47.9) | 23 (41.1) | 35 (36.1) | 28 (45.2) | 43 (34.7) | 24 (39.3) | 57 (47.9) |
| Hypertension (%) | 156 (48.6) | 239 (47.0) | 36 (38.7) | 38 (33.6) | 30 (40.5) | 47 (41.6) | 43 (53.8) | 69 (47.9) | 47 (63.5) | 85 (61.6) |
| Monotherapy (%) | 136 (42.4) | 134 (26.4)* | 42 (45.2) | 34 (30.1) | 33 (44.6) | 30 (26.5) | 31 (38.8) | 38 (26.4) | 30 (40.5) | 32 (23.2)* |
| Concomitant therapy (%) | ||||||||||
| SU | 75 (23.4) | 165 (32.5)* | 28 (30.1) | 41 (36.3) | 20 (27.0) | 32 (28.3) | 18 (22.5) | 51 (35.4) | 9 (12.2) | 41 (29.7)* |
| BG | 56 (17.4) | 112 (22.0)* | 14 (15.1) | 28 (24.8) | 13 (17.6) | 31 (27.4) | 16 (20.0) | 22 (15.3) | 13 (17.6) | 31 (22.5)* |
| TZD | 54 (16.8) | 97 (19.1)* | 9 (9.7) | 10 (8.8) | 8 (10.8) | 20 (17.7) | 15 (18.8) | 33 (22.9) | 22 (29.7) | 34 (24.6)* |
Values are presented as n (%) or mean ± standard deviation. *Significantly different at P < 0.05. Values were compared between the ipragliflozin and placebo groups within each body mass index (BMI) category using Fisher's exact test for categorical variables or independent‐samples t‐tests for continuous variables. BG, biguanide; DM, diabetes mellitus; SU, sulfonylurea; TZD, thiazolidinedione; WC, waist circumference.